Oncolytic viruses (OVs) are a class of viruses that can selectively replicate in and lyse cancer cells, and subsequent spread with a tumor while not causing damage to normal cells. They have tremendous therapeutic potential to target and kill cancerous cell. Oncolytic virotherapy is an innovative treatment modality which uses replication competent viruses to destroy malignant cancers.
With years of experience in research of oncolytic viruses as well as our QVirusTM platform, Creative Biogene expeditiously moves your oncolytic program forward for initial early-stage clinical evaluation. Creative Biogene provides a broad range of oncolytic virus engineering scope including herpes simplex virus, adenovirus, measles virus, vaccinia virus, vescilar stomatitis virus, and so on.
We provide customized, reliable and high-quality oncolytic virus therapy development services ranging from virus engineering, cell assays to animal testing. Various types of oncolytic viruses engineering systems have been established standardly to facilitate oncolytic virus development with less time and reduced budget. GMP-compliant manufacture of oncolytic virus is also included in our services.
Our Service Includes
- Oncolytic virus construction
- Oncolytic virus engineering
- Oncolytic virus validation
- Disease-specific oncolytic virotherapy development
Herpes simplex virus (HSV)
The most recent phase III trial data on a HSV-based oncolytic virus (T-VEC) show substantial improvement in objective and durable responses over the control arm in melanoma patients, prompting speculation that a virotherapy may receive FDA approval for clinical use in the very near future.
Adenoviruses have two early genes, E1A and E1B, which are essential for replication and need to be attenuated for oncolytic purpose. Coated protein modification is to increase target specificity of adenovirus to tumor cells, and thus alters viral tropism. Adenovirus can also be modified through transcriptional targeting, such as driving E1A and E1B gene under promoter of TERT (specifically expressed in a range of cancers). Adenoviral replication can also be controlled using microRNAs (miRNA) artificial target sites or miRNA response elements (MREs). Differential expression of miRNAs between healthy tissues and tumors permit to engineer oncolytic viruses to have their ability to replicate impaired in those tissues of interest while allowing its replication in the tumor cells.
Zhang S X. Turning killer into cure—the story of oncolytic herpes simplex viruses. Discovery medicine, 2015, 20(111): 303-309.
Wickham T J. Ligand-directed targeting of genes to the site of disease. Nature medicine, 2003, 9(1): 135.
Ylösmäki E, Hakkarainen T, Hemminki A, et al. Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. Journal of virology, 2008, 82(22): 11009-11015.